(Q30224497)

English

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

influenza vaccine

1 reference

based on heuristic

inferred from title

Markus Alexander Zeitlinger

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Herwig Kollaritsch

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Otfried Kistner

7

object named as

Otfried Kistner

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

5

object named as

Sandor Fritsch

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Hartmut J Ehrlich

12

object named as

Hartmut J Ehrlich

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

13

object named as

P Noel Barrett

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Maikel V W van der Velden

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Gerald Aichinger

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Eva Maria Pöllabauer

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Alexandra Löw-Baselli

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Karima Benamara

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Markus Müller

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Timo Vesikari

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

language of work or name

0 references

publication date

8 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

43

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

6127-6135

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Acquisition of human-type receptor binding specificity by new H5N1 influenza virus sublineages during their emergence in birds in Egypt.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

The H5N1 manuscript redaction controversy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Engineered H5N1: a rare time for restraint in science

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

H5N1: Flu transmission work is urgent

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

The NSABB recommendations: rationale, impact, and implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Laboratory creation of a highly transmissible H5N1 influenza virus: balancing substantial risks and real benefits

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Science should be in the public domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Mammalian-transmissible H5N1 influenza: the dilemma of dual-use research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Human infection with highly pathogenic H5N1 influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Update on avian influenza A (H5N1) virus infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Probable person-to-person transmission of avian influenza A (H5N1)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Strategies for mitigating an influenza pandemic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Algorithm AS 183: An Efficient and Portable Pseudo-Random Number Generator

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Comparison of influenza serological techniques by international collaborative study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Mitigation strategies for pandemic influenza in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 month

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Molecular programming of B cell memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Plasma cells negatively regulate the follicular helper T cell program

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.077

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.07.077

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884662%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30224497&oldid=1602717619"